Royal Philips Acquires CardioProlific
June 29, 2017—Royal Philips announced the acquisition of CardioProlific Inc., which is developing catheter-based thrombectomy approaches to treat peripheral vascular disease. Financial details of the transaction will not be disclosed. CardioProlific is a privately held company based in California.
According to Philips, CardioProlific’s technologies are complementary to the company's portfolio of image-guided therapy devices and to the portfolio of Spectranetrics Corporation, which Philips recently announced it would acquire.
The development of CardioProlific’s differentiated thrombectomy technologies will combine with Philip's suite of image-guided therapy solutions to address the treatment of peripheral vascular disease. Philips’ image-guided therapy portfolio includes interventional imaging systems, planning and navigation software, interventional devices (both diagnostic and therapeutic catheters), and a range of services.